Cargando…

Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

OBJECTIVE: To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. METHODS: 88 patients with advanced NSCLC treated in the Oncology Department of ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yinhua, Shi, Xiuhua, Qi, Qinghua, Ye, Bin, Zou, Zhaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694967/ https://www.ncbi.nlm.nih.gov/pubmed/34956561 http://dx.doi.org/10.1155/2021/2338800

Ejemplares similares

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report
por: Wu, Rui, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study
por: Wu, Jianhui, et al.
Publicado: (2023)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
por: Yu, Lian, et al.
Publicado: (2022)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
por: Zhou, Lingxiao, et al.
Publicado: (2023)

Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study
por: Dai, Yi-Jun, et al.
Publicado: (2023)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
por: Ye, Wenling, et al.
Publicado: (2023)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
por: Qi, Wenbo, et al.
Publicado: (2023)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients
por: Tian, Jizheng, et al.
Publicado: (2023)

Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study
por: Yang, Shengjie, et al.
Publicado: (2020)

A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors
por: Li, Shu-hui, et al.
Publicado: (2023)

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
por: Fang, Yu, et al.
Publicado: (2023)

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review
por: Wan, Yuchen, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study
por: Jiang, Hong-Tao, et al.
Publicado: (2021)

Efficacy and safety of anlotinib as a third-line treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
por: Zha, Bowen, et al.
Publicado: (2022)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
por: Rakké, Yannick Sebastiaan, et al.
Publicado: (2020)

Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study
por: Ye, Xuanting, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
por: Gong, Jinhong, et al.
Publicado: (2021)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer
por: Hou, Xinlei, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer
por: Zheng, Wubin, et al.
Publicado: (2022)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
por: Wang, Hai-ying, et al.
Publicado: (2020)

Effects of Camrelizumab Combined with First-Line Chemotherapy on Serum SCC, VEGF Levels, and Adverse Reactions in Patients with Advanced Squamous Cell Carcinoma of the Lung
por: Wang, Zizong, et al.
Publicado: (2022)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
por: Zhu, Qiuyan, et al.
Publicado: (2023)

Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report
por: Zhu, Shu-Guang, et al.
Publicado: (2022)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
por: Yuan, Li, et al.
Publicado: (2023)

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
por: Hao, Yan-Yan, et al.
Publicado: (2021)

The efficacy and safety of anlotinib treatment for advanced lung cancer
por: Shao, Lan, et al.
Publicado: (2019)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
por: Wang, Kunlun, et al.
Publicado: (2020)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ssgkfe95fi1kl8k18bmoilabh